JPMorgan Chase & Co’s CytomX Therapeutics CTMX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$638 Sell
281
-105,013
-100% -$238K ﹤0.01% 5782
2025
Q1
$66.9K Sell
105,294
-706,336
-87% -$449K ﹤0.01% 4922
2024
Q4
$836K Buy
811,630
+811,349
+288,736% +$836K ﹤0.01% 3899
2024
Q3
$332 Hold
281
﹤0.01% 5773
2024
Q2
$343 Hold
281
﹤0.01% 5703
2024
Q1
$613 Hold
281
﹤0.01% 5675
2023
Q4
$436 Sell
281
-1,449
-84% -$2.25K ﹤0.01% 5905
2023
Q3
$2.23K Hold
1,730
﹤0.01% 5573
2023
Q2
$2.98K Hold
1,730
﹤0.01% 5376
2023
Q1
$3K Hold
1,730
﹤0.01% 5474
2022
Q4
$3K Sell
1,730
-2,672
-61% -$4.63K ﹤0.01% 5295
2022
Q3
$6K Buy
4,402
+1,425
+48% +$1.94K ﹤0.01% 5152
2022
Q2
$5K Sell
2,977
-302,055
-99% -$507K ﹤0.01% 5294
2022
Q1
$814K Sell
305,032
-2,197
-0.7% -$5.86K ﹤0.01% 3741
2021
Q4
$1.33M Sell
307,229
-13,037
-4% -$56.4K ﹤0.01% 3497
2021
Q3
$1.63M Sell
320,266
-21,269
-6% -$108K ﹤0.01% 3301
2021
Q2
$2.16M Buy
341,535
+269,329
+373% +$1.71M ﹤0.01% 3178
2021
Q1
$559K Sell
72,206
-8,318
-10% -$64.4K ﹤0.01% 3986
2020
Q4
$528K Sell
80,524
-11,781
-13% -$77.2K ﹤0.01% 3714
2020
Q3
$618K Sell
92,305
-7,275
-7% -$48.7K ﹤0.01% 3297
2020
Q2
$828K Sell
99,580
-76,433
-43% -$636K ﹤0.01% 3100
2020
Q1
$1.35M Sell
176,013
-192,992
-52% -$1.48M ﹤0.01% 2806
2019
Q4
$3.07M Buy
369,005
+234,743
+175% +$1.95M ﹤0.01% 2462
2019
Q3
$991K Buy
134,262
+6,969
+5% +$51.4K ﹤0.01% 3072
2019
Q2
$1.35M Sell
127,293
-7,166
-5% -$76.1K ﹤0.01% 2901
2019
Q1
$1.45M Sell
134,459
-8,611
-6% -$92.6K ﹤0.01% 2833
2018
Q4
$2.16M Sell
143,070
-7,514
-5% -$113K ﹤0.01% 2606
2018
Q3
$2.79M Buy
150,584
+10,653
+8% +$197K ﹤0.01% 2603
2018
Q2
$3.2M Sell
139,931
-61,130
-30% -$1.4M ﹤0.01% 2523
2018
Q1
$5.72M Sell
201,061
-42,478
-17% -$1.21M ﹤0.01% 2123
2017
Q4
$5.14M Buy
243,539
+4,989
+2% +$105K ﹤0.01% 2230
2017
Q3
$4.31M Sell
238,550
-4,200
-2% -$75.9K ﹤0.01% 2245
2017
Q2
$3.76M Buy
242,750
+56,972
+31% +$883K ﹤0.01% 2288
2017
Q1
$3.21M Buy
185,778
+157,261
+551% +$2.72M ﹤0.01% 2349
2016
Q4
$313K Buy
+28,517
New +$313K ﹤0.01% 3474